
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A state-of-the-art gynecologic oncology review on High-Grade Serous Ovarian Carcinoma (HGSOC), evaluating primary cytoreductive surgery vs. interval debulking, CA-125 kinetics, germline/somatic BRCA and HRD testing, and maintenance PARP inhibitors (Olaparib, Niraparib).
CRITICAL CLINICAL RED FLAG: Persistent abdominal bloating, early satiety, pelvic pain, and increased urinary frequency lasting more than 12 days a month in postmenopausal women requires immediate pelvic transvaginal ultrasound and serum CA-125 measurement.
Over 80% of High-Grade Serous Ovarian Carcinomas (HGSOC) originate from Serous Tubal Intraepithelial Carcinomas (STIC) in the fimbriated end of the fallopian tubes rather than the ovarian surface epithelium. Characterized by universal TP53 mutations and high genomic instability.
Homologous Recombination Deficiency (HRD): Present in up to 50% of HGSOC cases (BRCA1/2 mutations or genomic scar positivity).
Peritoneal Seeding: Ovarian cancer exfoliates malignant cells into peritoneal fluid, seeding the omentum, diaphragm, and bowel mesentery.
The goal of cytoreductive surgery is complete macroscopic resection (R0, zero residual disease):
Primary Debulking Surgery (PDS): Total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, and peritonectomy.
Neoadjuvant Chemotherapy (NACT): 3 cycles of Paclitaxel (175 mg/m²) + Carboplatin (AUC 5-6) administered prior to Interval Debulking Surgery (IDS) in patients with high-burden unresectable disease or poor performance status.
"Achieving complete macroscopic cytoreduction (R0 with zero residual visible disease) combined with frontline PARP inhibitor maintenance yields unprecedented long-term remission in ovarian cancer." — Dr. Neha Gupta

Following platinum-response, oral PARP inhibitors (Olaparib for BRCA-mutated, Niraparib for HRD-positive/all-comers) inhibit single-strand DNA break repair, driving HRD cancer cells into catastrophic double-strand breaks and synthetic lethality.
CLINICAL CAUTION: Laparoscopic aspiration of an intact cystic ovarian mass is strictly contraindicated due to the risk of tumor spillage converting a curable Stage I cancer into an advanced Stage IC.
Clinical evaluation and serum CA-125 every 3 months for 2 years, combined with cross-sectional CT/PET imaging for any biological surge, enables early intervention.
1. Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO-1 Trial) — NEJM, 2018; 379: 2495-2505.
2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (PRIMA Trial) — NEJM, 2019; 381: 2391-2402.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.